An allosteric antagonist of CXCR1 and CXCR2
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Reparixin

Item No. 17350

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(αR)-α-methyl-4-(2-methylpropyl)-N-(methylsulfonyl)-benzeneacetamide
CAS Number
266359-83-5
Synonyms
  • DF 1681Y
  • Repertaxin
Molecular Formula
C14H21NO3S
Formula Weight
283.4
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 15 mg/mlEthanol: 25 mg/mlPBS (pH 7.2): 0.2 mg/ml
λmax
220 nm
SMILES
CC(C)CC1=CC=C([C@@H](C)C(NS(C)(=O)=O)=O)C=C1
InChi Code
InChI=1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
InChi Key
KQDRVXQXKZXMHP-LLVKDONJSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $29

    Add

    5 mg

    $57

    Add

    10 mg

    $99

    Add

    25 mg

    $212

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Reparixin is an allosteric antagonist of chemokine (C-X-C motif) receptor 1 (CXCR1) and CXCR2 (IC50s = 1 and 100 nM, respectively).1 In vivo, reparixin (3, 15, and 30 mg/kg) reduces ischemia and reperfusion-induced hepatic polymorphonuclear leukocyte (PMN) recruitment, hepatic myeloperoxidase (MPO) levels, and serum alanine transaminase (ALT) levels in a rat model of hepatic ischemia. It decreases systolic blood pressure in spontaneously hypertensive rats when administered at a dose of 5 mg/kg.2 Reparixin, in combination with docetaxel (Item No. 11637), reduces tumor volume and the number of intratumor cancer stem cells in a SUM159 triple-negative breast cancer (TNBC) mouse xenograft model.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bertini, R., Allegretti, M., Bizzarri, C., et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proc. Natl. Acad. Sci. USA 101(32), 11791-11796 (2004).

    2. Kim, H.Y., Choi, J.H., Kang, Y.J., et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol. Pharm. Bull. 34(1), 120-127 (2011).

    3. Ginestier, C., Liu, S., Diebel, M.E., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120(2), 485-497 (2010).

    Product Citations

    Martínez-Burgo, B., Cobb, S.L., Pohl, E., et al. A C-terminal CXCL8 peptide based on chemokine-glycosaminoglycan interactions reduces neutrophil adhesion and migration during inflammation. Immunology 157(2), 173-184 (2019).